Analytical approaches for lipidomics and its potential applications in neuropsychiatric disorders
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: In this review, the authors discuss an overview of lipidomics followed by in-depth discussion of its application to the study of human diseases, including extraction methods of lipids, analytical techniques and clinical research in neuropsychiatric disorders. METHODS: Lipidomics is a lipid-targeted metabolomics approach aiming at the comprehensive analysis of lipids in biological systems. Recent technological advancements in mass spectrometry and chromatography have greatly enhanced the development and applications of metabolic profiling of diverse lipids in complex biological samples. RESULTS: An effective evaluation of the clinical course of diseases requires the application of very precise diagnostic and assessment approaches as early as possible. In order to achieve this, "omics" strategies offer new opportunities for biomarker identification and/or discovery in complex diseases and may provide pathological pathways understanding for diseases beyond traditional methodologies. CONCLUSIONS: This review highlights the importance of lipidomics for the future perspectives as a tool for biomarker identification and discovery and its clinical application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The HPA axis in major depression: classical theories and new developments
Pariante, C. M., & Lightman, S. L. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.006 · Cited by 2,009
Hippocampal atrophy in recurrent major depression
Sheline, Y. I., Wang, P. W., Gado, M. H., Csernansky, J. G., & Vannier, M. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.3908 · Cited by 1,932 · cited 2×
“2014), the hyperactivity of the hypothalamic–pituitary–adrenal axis (Pariante and Lightman 2008), hippocampal atrophy (Sheline et al. 1996; Campbell and Macqueen 2004), and glial reduction in the subgenual prefrontal cortex (Ongur et al.”
BackgroundGlial reduction in the subgenual prefrontal cortex in mood disorders
Öngür, D., Drevets, W. C., & Price, J. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13290 · Cited by 1,525 · cited 2×
“1996; Campbell and Macqueen 2004), and glial reduction in the subgenual prefrontal cortex (Ongur et al. 1998).”
BackgroundClinical diagnosis of depression in primary care: a meta-analysis
Mitchell, A. J., Vaze, A., & Rao, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60879-5 · Cited by 1,251 · cited 1×
“However, the diagnosis of MDD is still challenging due to the high error rate (Mitchell et al. 2009).”
BackgroundMoghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035 · cited 2×
“association with neuronal loss and disease worsening over time (Moghaddam and Javitt 2012).”
BackgroundResultHan, X., & Gross, R. W. (2003) · Journal of Lipid Research · doi:10.1194/jlr.r300004-jlr200 · Cited by 914
Omega-3 Fatty Acids: Evidence Basis for Treatment and Future Research in Psychiatry
Freeman, M. P., Hibbeln, J. R., Wisner, K. L., Davis, J. M., Mischoulon, D., Peet, M., Keck, P. E., Marangell, L. B., Richardson, A. J., Lake, J., et al. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1217 · Cited by 709 · cited 1×
“Furthermore, a meta-analysis of clinical trials of omega-3 polyunsaturated fatty acids (PUFAs) in major depressed patients showed a significant improvement (Freeman et al. 2006).”
BackgroundBelmaker, R. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035354 · Cited by 473
Rao, J. S., Harry, G. J., Rapoport, S. I., & Kim, H. W. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.47 · Cited by 432 · cited 2×
“…studies indicate that brain AA (20:4n-6) metabolism is upregulated in the BD brain in association with neuroinflammation and excitotoxicity (Rao et al. 2010; Kim et al. 2011), and mood stabilisers (lithium, carbamazepine, olanzapine and valproate) that are effective in BD patients, when…”
BackgroundOmega-3 for Bipolar Disorder: Meta-Analyses of Use in Mania and Bipolar Depression
Sarris, J., Mischoulon, D., & Schweitzer, I. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10r06710 · Cited by 284 · cited 2×
“Some evidence indicates that eicosapentaenoic acid (EPA) is the active n-3 PUFA responsible for moodaltering effects in n-3 PUFA supplementation studies of depression (Sublette et al. 2011; Sarris et al. 2012).”
BackgroundMetabolomic Mapping of Atypical Antipsychotic Effects in Schizophrenia
Kaddurah-Daouk, R., McEvoy, J., Baillie, R. A., Lee, D., Yao, J. K., Doraiswamy, P. M., & Krishnan, K. R. R. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002000 · Cited by 262 · cited 3×
“The organic phase is specifically denser and contains lipids that can be isolated from it with high efficiency (Hermansson et al. 2005; Kaddurah-Daouk et al. 2007).”
BackgroundLipidomics of Alzheimer's disease: current status
Wood, P. L. (2012) · Alzheimer's Research & Therapy · doi:10.1186/alzrt103 · Cited by 167
Demirkan, A., Isaacs, A., Ugocsai, P., Liebisch, G., Struchalin, M., Rudan, I., Wilson, J. F., Pramstaller, P. P., Gyllensten, U., Campbell, H., et al. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.11.001 · Cited by 163 · cited 1×
“A Dutch familybased lipidomics study has revealed that the absolute level of phosphatidylcholine (PC-O 36:4) in plasma is associated with depression and anxiety symptoms (Demirkan et al. 2013).”
BackgroundNygren, H., Seppänen-Laakso, T., Castillo, S., Hyötyläinen, T., & Orešič, M. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-61737-985-7_15 · Cited by 154 · cited 2×
“…example, ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS) and UPLC coupled to ion mobility (IM)-QTOF-MS are more appropriate for untargeted lipidomics, both allowing fast analysis and high-resolution MS detection (Nygren et al. 2011).”
MethodLiu, S., Sjövall, J., & Griffiths, W. J. (2003) · Analytical Chemistry · doi:10.1021/ac0346297 · Cited by 141
McEvoy, J., Baillie, R. A., Zhu, H., Buckley, P., Keshavan, M. S., Nasrallah, H. A., Dougherty, G. G., Yao, J. K., & Kaddurah-Daouk, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068717 · Cited by 127 · cited 1×
“A recent study has demonstrated significant down-regulation of several n-3 and n-6 PUFAs compositions in PE and PC lipid classes in the blood plasma of first episode of SCZ (McEvoy et al. 2013).”
BackgroundIdentification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods
Fonteh, A. N., Harrington, R. J., Huhmer, A. F., Biringer, R. G., Riggins, J. N., & Harrington, M. G. (2006) · Disease Markers · doi:10.1155/2006/202938 · Cited by 113 · cited 2×
“Therefore, drastic alterations in lipid composition may have significant pathological consequences (Fonteh et al. 2006).”
BackgroundImpaired Plasmalogens in Patients with Schizophrenia
Kaddurah-Daouk, R., McEvoy, J., Baillie, R., Zhu, H., K. Yao, J., Nimgaonkar, V. L., Buckley, P. F., Keshavan, M. S., Georgiades, A., & Nasrallah, H. A. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.02.019 · Cited by 89 · cited 2×
“In conclusion, several studies showed significant changes in prefrontal cortex FA concentrations, particularly within cholesteryl ester and abnormalities in plasmalogen levels of SCZ patients compared with controls, (Kaddurah-Daouk et al. 2012; Taha et al. 2013).”
BackgroundLiu, J. J., Galfalvy, H. C., Cooper, T. B., Oquendo, M. A., Grunebaum, M. F., Mann, J. J., & Sublette, M. E. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m07970 · Cited by 73
Orešič, M., Seppänen-Laakso, T., Sun, D., Tang, J., Therman, S., Viehman, R., Mustonen, U., van Erp, T. G., Hyötyläinen, T., Thompson, P., et al. (2012) · Genome Medicine · doi:10.1186/gm300 · Cited by 5
Cited by
Lipidomics: Techniques, Applications, and Outcomes Related to Biomedical Sciences
Yang, K., & Han, X. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2016.08.010 · Cited by 588
Metabolic Profiling Identifies Phospholipids as Potential Serum Biomarkers for Schizophrenia
Wang, D., Cheng, S. L., Fei, Q., Gu, H., Raftery, D., Cao, B., Sun, X., Yan, J., Zhang, C., & Wang, J. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2018.12.008 · Cited by 73
Adaptation of Lipid Profiling in Depression Disease and Treatment: A Critical Review
Pinto, B., Conde, T., Domingues, I., & Domingues, M. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042032 · Cited by 51
“The use of lipidomics to monitor progression of therapeutics and for a better prognosis could translate into a more accurate strategy to treat patients with MDD and predict its outcome [86].”
BackgroundWang, D., Sun, X., Maziade, M., Mao, W., Zhang, C., Wang, J., & Cao, B. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2020.1769188 · Cited by 26
Metadata
- Authors
- Sethi, S., Hayashi, M. A., Sussulini, A., Tasic, L., & Brietzke, E.
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2016-01-26
- Volume
- 18
- Issue
- 7
- Pages
- 506-520
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2159908955
- Cited by
- 44
- References
- 20
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.